Episode Details

Dr. Space, host of The Space Show, recently hosted a compelling conversation with Ben Roberts, founder and CEO of Skyworker Work Group Finance and Advisory Surfaces LLC. The discussion centered on financing space business entrepreneurs developing health and material products in microgravity. They explored how the unique conditions of space, specifically the absence of gravity—can be leveraged to manufacture advanced materials and medical goods. These include protein crystals for medicines, engineered nanoparticles, 3D-printed cardiac tissue, and accelerated aging models for studying diseases such as Parkinson’s and Alzheimer’s.

Although the microgravity economy remains in its early stages, with no companies yet achieving significant commercial profitability, several ventures are nearing viability. Experts believe these companies could access substantial markets within the next 3–5 years, once regulatory hurdles are cleared.

Our guest Ben outlined the foundations of in-space manufacturing. He explained how microgravity eliminates forces like sedimentation and convection, enabling the creation of next-generation materials and technologies that may no longer be feasible to produce on Earth. While the concept has been explored for decades, real progress has emerged only in the past 5–6 years, with more defined use cases nearing commercialization.

Key applications discussed include:

* High-quality protein crystals for drug development;

* Advanced nanoparticles;

* 3D-printed cardiac tissue;

* Accelerated aging studies for neurological diseases.

Ben likened the microgravity economy to the startup ecosystem 15 years ago—rich in innovation and investor interest, but still pre-revenue. He pointed out that many space-based life science companies are close to proving commercial viability. These businesses could tap into eight- or nine-figure markets once they secure regulatory approvals.

As an example, he cited LambdaVision,a company developing artificial retinas. Initially funded through federal R&D grants, the company now requires relatively modest monthly investments ($25,000–$50,000) to complete clinical trials.

Ben discussed the broader political and funding environment. While microgravity research is not currently a federal priority, bipartisan coalitions are emerging in Congress. He noted that most ventures are focused on low Earth orbit (LEO), where zero gravity can be achieved without needing to go to cislunar space. The sector remains early in the "hype curve," but Ben was optimistic that commercial breakthroughs—such as personalized cancer treatments—could arrive within 3–5 years, potentially at a fraction of traditional pharmaceutical development costs.

A listener email from Jane raised the issue of limited awareness among doctors regarding space-based medical solutions, like printing replacement menisci in orbit for people with damaged knees. She also suggested that doctors dismiss such ideas or products thus patients remain in the dark about the progress unless they start internet searches themselves. Ben acknowledged this gap but noted that companies such as Redwire are actively collaborating with medical institutions. Responding to another listener, Jerry, he addressed the uncertain future of the ISS and the coming role of private space stations. Ben suggested that some manufacturing processes may not require constant human presence and could benefit from uncrewed or short-duration orbital platforms.

Our guest highlighted growing international interest, including from China, in space manufacturing. He noted that many ventures in this sector can operate with relatively modest capital (eight figures), making global partnerships feasible—especially for life sciences applications. Although many U.S. companies are focused on other space segments, the microgravity manufacturing niche is largely populated by small U.S.-based firms. On space touris